As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.
11 Analysts have issued a PolyNovo Limited forecast:
11 Analysts have issued a PolyNovo Limited forecast:
Jun '25 |
+/-
%
|
||
Revenue | 128 128 |
22%
22%
|
|
Gross Profit | 123 123 |
24%
24%
|
|
EBITDA | 9.64 9.64 |
82%
82%
|
|
EBIT (Operating Income) EBIT | 6.95 6.95 |
123%
123%
|
|
Net Profit | 13 13 |
151%
151%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. The company is headquartered in Melbourne, Victoria and currently employs 301 full-time employees. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
Head office | Australia |
CEO | Mr. Raote |
Employees | 282 |
Website | polynovo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.